Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, in combination with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - results of a phase I dose escalation study

Ítems similars

• Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
  per: Hurwitz, Herbert I., et al.
  Publicat: (2015)
• The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
  per: Bobardt, Michael, et al.
  Publicat: (2019)
• The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
  per: Bobardt, Michael, et al.
  Publicat: (2020)
• DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death
  per: Thibault, Benoît, et al.
  Publicat: (2018)
• Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model
  per: Bellaye, Pierre-Simon, et al.
  Publicat: (2018)